标题:
Inhibition of HDAC6 blocks the development and progression of peritoneal fibrosis
讲者:
刘娜
单位:
上海市东方医院同济大学附属东方医院
播放:
1903
论文摘要:
Peritoneal fibrosis is the primary cause for patients to drop out from peritoneal dialysis (PD). There is a report showing that activation of class I histone deactylases (HDACs) are correlated with development of peritoneal fibrosis. However, it remains unclear whether HDAC6, one of class II HDAC isoforms, could play a role in peritoneal fibrosis. In this study, we investigated the effect of Tubastatin A (TA), a highly selective HDAC6 inhibitor, on the initiation and development of peritoneal fibrosis. In a mouse model of peritoneal fibrosis induced by daily intraperitoneal administration of 4.25% peritoneal dialysis solution for 28 days, increased collagen deposition and the thickening of the submesothelial region were evident. Administration with TA attenuated the development and progression of peritoneal fibrosis. This was accompanied by induction of histone H3 acetylation, inhibition of transforming growth factor (TGF) receptor expression and Smad-3 phosphorylation, as well as preservation of Smad-7 expression. TA treatment also inhibited phosphorylation of epidermal growth factor receptor (EGFR), and nuclear factor (NF)-κB and signal transducer and activator of transcription 3. Furthermore, HDAC6 inhibition suppressed a variety of inflammatory cytokines, reduced the infiltration of macrophages to the injured peritoneum, and inhibited peritoneal increase of CD31 (+) blood vessels and vascular endothelial growth factor (+) cells after high glucose injury. In human peritoneal mesothelial cells (HPMCs), we also observed that TA treatment dose-dependently suppressed TGF-b1-induced expression of α-SMA and collagen-I, as well as phosphorylation of Smad3. These results suggest that TA can block the progression of peritoneal fibrosis by upregulation of histone acetylation, and subsequently inhibition of multiple fibrogentic signaling pathway activation and inflammatory responses as well as blockade of angiogenesis. Thus, targeted inhibition of HDAC6 could be an effective and potential therapy to treat peritoneal fibrosis in human.